TY  - JOUR
Y1  - 2018/01//
TI  - A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease
VL  - 12
A1  - Brinkmalm, G
A1  - Sjodin, S
A1  - Simonsen, AH
A1  - Hasselbalch, SG
A1  - Zetterberg, H
A1  - Brinkmalm, A
A1  - Blennow, K
KW  - Alzheimer's disease
KW  -  biomarker
KW  -  cerebrospinal fluid
KW  -  mass spectrometry
KW  -  parallel reaction monitoring
EP  - 13
IS  - 1
ID  - discovery10065862
UR  - https://doi.org/10.1002/prca.201700131
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
JF  - Proteomics Clinical Applications
PB  - WILEY-V C H VERLAG GMBH
SN  - 1862-8354
N2  - Scope: The aim of this study was to develop and evaluate a parallel reactionmonitoring mass spectrometry (PRM-MS) assay consisting of a panel ofpotential protein biomarkers in cerebrospinal fluid (CSF).Experimental design: Thirteen proteins were selected based on theirassociation with neurodegenerative diseases and involvement in synapticfunction, secretory vesicle function, or innate immune system. CSF sampleswere digested and two to three peptides per protein were quantified usingstable isotope-labeled peptide standards.Results: Coefficients of variation were generally below 15%. Clinicalevaluation was performed on a cohort of 10 patients with Alzheimer?s disease(AD) and 15 healthy subjects. Investigated proteins of the granin familyexhibited the largest difference between the patient groups. Secretogranin-2(p<0.005) and neurosecretory protein VGF (p<0.001) concentrations werelowered in AD. For chromogranin A, two of three peptides had significantlylowered AD concentrations (p<0.01). The concentrations of the synapticproteins neurexin-1 and neuronal pentraxin-1, as well as neurofascin werealso significantly lowered in AD (p<0.05). The other investigated proteins,?2-microglobulin, cystatin C, amyloid precursor protein, lysozyme C,neurexin-2, neurexin-3, and neurocan core protein, were not significantlyaltered.Conclusion and clinical relevance: PRM-MS of protein panels is a valuabletool to evaluate biomarker candidates for neurodegenerative disorders.
AV  - public
ER  -